Letters

Corresponding Author: Massimo Girardis, MD, Cattedra di Anestesia e Rianimazione, Azienda Ospedaliero Universitaria di Modena, L.go del Pozzo 71, 41100 Modena, Italy (girardis.massimo@unimo.it).

Conflict of Interest Disclosures: Both authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.


CORRECTION

Omission of Data: In the Original Investigation entitled “Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial” published in the December 20, 2016, issue of JAMA, data were omitted. The Design, Setting, and Participants section of the Abstract should have reported that “45 participants were randomized to receive pritelivir.” In the Results section of the Abstract, the relative risk during valacyclovir treatment should have been reported as “0.42.” In Table 1, the upper bound of the confidence intervals in the “HSV DNA log10 copies/mL” subsection should have been reported as “0.5,” “0.0,” and “1.0,” respectively. The second and third row stubs in the “Clinical End Points” section should have read “Recurrence or incidence rate” and “Days with pain,” respectively. This article was corrected online.


Incorrect Values and Excluded Units of Measure: In the Original Investigation entitled “Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015” published in the January 10, 2017, issue of JAMA, incorrect values for changes in loss of disability-adjusted life-years (DALYs) were reported in the Results section of the Abstract. For loss of DALYs associated with systolic blood pressure of 140 mm Hg or higher, the loss increased from 95.9 million (95% uncertainty interval [UI], 87.0-104.9 million) to 143.0 million (95% UI, 130.2-157.0 million). Additionally, some of the units of measure for rows in Table 1 were excluded. The rows that were labeled to report values for “Individuals” and “Deaths” have been corrected to read: “Individuals, thousands” and “Deaths, thousands.” This article was corrected online.


Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment and the ICMJE Form for Disclosure of Potential Conflicts of Interest are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editor: Jody W. Zylke, MD, Deputy Editor.